Figure 4
From: miR-96-5p targets PTEN to mediate sunitinib resistance in clear cell renal cell carcinoma
Modulation of sunitinib sensitivity by the miR-96-5p/PTEN axis in CCRCC patient-derived xenografts (PDXs). (a) H&E staining images of tumors from original sunitinib-resistant and sunitinib-sensitive patients and their corresponding PDXs (scale bar = 50 μm). (b, c) PDX models were divided into two treatment groups: vehicle and 40 mg/kg sunitinib. Body weight and tumor volumes were assessed for changes over time (Vehicle n = 4; sunitinib n = 4, mean ± s.e.m., *P < 0.05, ***P < 0.001, one-way ANOVA). (d, e) Comparison of the expression of PTEN between sunitinib-resistant (d) and sunitinib-sensitive PDX (e) at 0 and 28 days; GAPDH, internal control. (f, g) PTEN (f) and miR-96-5p (g) expression from tissue of sunitinib-resistant PDX, compared with the sunitinib-sensitive counterparts (mean ± s.e.m., *P < 0.05, ***P < 0.001, one-way ANOVA, n = 3).
